{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:28:59Z","timestamp":1787236139165,"version":"build-2736575974"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["ISRCTN84013636"],"award-info":[{"award-number":["ISRCTN84013636"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["ISRCTN84681538"],"award-info":[{"award-number":["ISRCTN84681538"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["NCT02070120"],"award-info":[{"award-number":["NCT02070120"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.euo.2026.04.017","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T10:32:17Z","timestamp":1784025137000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Outcomes of Intermediate Risk Non\u2013muscle-invasive Bladder Cancer Receiving Adjuvant Treatment: A Pooled Analysis of Four Randomized Controlled Trials"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6119-4043","authenticated-orcid":false,"given":"Wei Shen","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Porta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Ackerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thenmalar","family":"Vadiveloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Penegar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Vale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh","family":"Mostafid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme","family":"MacLennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Heer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2026.04.017_b0005","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1007\/s12325-020-01616-3","article-title":"The impact of progression on healthcare resource utilization and costs among patients with high-grade non-muscle invasive bladder cancer after bacillus Calmette-Gu\u00e9rin therapy: a retrospective SEER-medicare analysis","volume":"38","author":"Yang","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.euo.2026.04.017_b0010","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology guidelines on non\u2013muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.04.017_b0015","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ctrv.2016.05.002","article-title":"Management of non-muscle invasive bladder cancer: a comprehensive analysis of guidelines from the United States, Europe and Asia","volume":"47","author":"Tan","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.euo.2026.04.017_b0020","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.04.017_b0025","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","article-title":"Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model","volume":"182","author":"Fernandez-Gomez","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2026.04.017_b0030","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1038\/bjc.2013.372","article-title":"Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder","volume":"109","author":"Xylinas","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.euo.2026.04.017_b0035","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.eururo.2011.05.033","article-title":"The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Gu\u00e9rin: external validation of the EORTC risk tables","volume":"60","author":"Fernandez-Gomez","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.04.017_b0040","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.euo.2022.05.005","article-title":"Intermediate-risk non\u2013muscle-invasive bladder cancer: updated consensus definition and management recommendations from the International Bladder Cancer Group","volume":"5","author":"Tan","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.04.017_b0045","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.eururo.2022.08.003","article-title":"Adjuvant intravesical chemohyperthermia versus passive chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer (HIVEC-II): a Phase 2, open-label, randomised controlled trial","volume":"83","author":"Tan","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.04.017_b0050","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200092","article-title":"A randomized trial of PHOTOdynamic surgery in non-muscle-invasive bladder cancer","volume":"1","author":"Heer","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.euo.2026.04.017_b0055","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.eururo.2018.09.020","article-title":"BOXIT-A randomised Phase III placebo-controlled trial evaluating the addition of celecoxib to standard treatment of transitional cell carcinoma of the bladder (CRUK\/07\/004)","volume":"75","author":"Kelly","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.04.017_b0060","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/bju.15038","article-title":"Caliber: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer","volume":"125","author":"Mostafid","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2026.04.017_b0065","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) - 2019 update","volume":"76","author":"Babjuk","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.04.017_b0070","unstructured":"National Institute for Health and Care Excellence. Bladder cancer: diagnosis and management; 2015. https:\/\/www.nice.org.uk\/guidance\/ng2\/resources\/bladder-cancer-diagnosis-and-management-pdf-51036766405."},{"key":"10.1016\/j.euo.2026.04.017_b0075","series-title":"Multiple imputation for nonresponse in surveys","author":"Rubin","year":"1987"},{"key":"10.1016\/j.euo.2026.04.017_b0080","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/01621459.1979.10481038","article-title":"Robust locally weighted regression and smoothing scatterplots","volume":"74","author":"Cleveland","year":"1979","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.euo.2026.04.017_b0085","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.euo.2022.04.003","article-title":"Oncologic surveillance after radical nephroureterectomy for high-risk upper tract urothelial carcinoma","volume":"5","author":"Martini","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.04.017_b0090","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2026.04.017_b0095","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1464-410X.2009.09153.x","article-title":"A 1-year maintenance after early adjuvant intravesical chemotherapy has a limited efficacy in preventing recurrence of intermediate risk non-muscle-invasive bladder cancer","volume":"106","author":"Serretta","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2026.04.017_b0100","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.euo.2023.06.011","article-title":"Sequential intravesical gemcitabine and docetaxel is an alternative to bacillus Calmette-Gu\u00e9rin for the treatment of intermediate-risk non-muscle-invasive bladder cancer","volume":"6","author":"Tan","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.04.017_b0105","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1097\/JU.0000000000003639","article-title":"International bladder cancer group intermediate-risk nonmuscle-invasive bladder cancer scoring system predicts outcomes of patients on active surveillance","volume":"210","author":"Tan","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2026.04.017_b0110","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.euo.2021.05.002","article-title":"Long-term follow-up and factors associated with active surveillance failure for patients with non\u2013muscle-invasive bladder cancer: the bladder cancer Italian active surveillance (BIAS) experience","volume":"5","author":"Contieri","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.04.017_b0115","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.euf.2023.03.025","article-title":"When and how to perform active surveillance for low-risk non-muscle-invasive bladder cancer","volume":"9","author":"Contieri","year":"2023","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2026.04.017_b0120","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/s41585-023-00789-0","article-title":"Clinical trial design for non-muscle-invasive bladder cancer","volume":"20","author":"Tan","year":"2023","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euo.2026.04.017_b0125","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.euo.2024.06.004","article-title":"Clinical validation of the intermediate-risk non\u2013muscle-invasive bladder cancer scoring system and substratification model proposed by the international bladder cancer group: a multicenter young academic urologists urothelial working group collaboration","volume":"7","author":"Soria","year":"2024","journal-title":"Eur Urol Oncol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126001276?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126001276?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T20:31:06Z","timestamp":1784147466000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931126001276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":25,"alternative-id":["S2588931126001276"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2026.04.017","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of Intermediate Risk Non\u2013muscle-invasive Bladder Cancer Receiving Adjuvant Treatment: A Pooled Analysis of Four Randomized Controlled Trials","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2026.04.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}